Jason Gerberry
Stock Analyst at B of A Securities
(3.97)
# 610
Out of 5,099 analysts
168
Total ratings
59.02%
Success rate
8.17%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $62 → $81 | $69.69 | +16.23% | 4 | Dec 9, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $86 → $97 | $79.19 | +22.49% | 7 | Dec 9, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $29 → $32 | $29.62 | +8.05% | 15 | Dec 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $230 → $247 | $165.50 | +49.24% | 6 | Nov 18, 2025 | |
| OCS Oculis Holding AG | Maintains: Buy | $30 → $29 | $20.48 | +41.60% | 4 | Nov 13, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $28 → $32 | $25.65 | +24.76% | 2 | Aug 26, 2025 | |
| IMVT Immunovant | Maintains: Buy | $33 → $30 | $23.32 | +28.64% | 6 | Aug 12, 2025 | |
| BHVN Biohaven | Maintains: Buy | $50 → $49 | $10.48 | +367.56% | 2 | Aug 12, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $173 → $176 | $148.43 | +18.57% | 6 | Aug 5, 2025 | |
| PROK ProKidney | Downgrades: Underperform | $3 → $1 | $2.17 | -53.92% | 4 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $23 | $32.77 | -29.81% | 2 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $46 | $41.84 | +9.94% | 3 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $157 → $137 | $43.44 | +215.38% | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $10 | $11.55 | -13.38% | 3 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $22.56 | +33.01% | 2 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $100 | $71.57 | +39.72% | 5 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $7.64 | +214.14% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $32.14 | -3.55% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $600 → $550 | $3.87 | +14,111.89% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $28.51 | +1.72% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $43.68 | +28.21% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $38.79 | -22.66% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $100 → $50 | $8.69 | +475.37% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $996.20 | -49.81% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $1.49 | +504.03% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $7.16 | +249.41% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $2.11 | +136.97% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $6.89 | +291.87% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $1.32 | +1,420.91% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $100 | $8.08 | +1,138.39% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $225.60 | -57.89% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $51.52 | +16.46% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $37 | $25.71 | +43.91% | 4 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $97.89 | -8.06% | 11 | Oct 17, 2019 |
Arrowhead Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $62 → $81
Current: $69.69
Upside: +16.23%
Ionis Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $86 → $97
Current: $79.19
Upside: +22.49%
Teva Pharmaceutical Industries
Dec 9, 2025
Maintains: Buy
Price Target: $29 → $32
Current: $29.62
Upside: +8.05%
Jazz Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $230 → $247
Current: $165.50
Upside: +49.24%
Oculis Holding AG
Nov 13, 2025
Maintains: Buy
Price Target: $30 → $29
Current: $20.48
Upside: +41.60%
Amphastar Pharmaceuticals
Aug 26, 2025
Maintains: Neutral
Price Target: $28 → $32
Current: $25.65
Upside: +24.76%
Immunovant
Aug 12, 2025
Maintains: Buy
Price Target: $33 → $30
Current: $23.32
Upside: +28.64%
Biohaven
Aug 12, 2025
Maintains: Buy
Price Target: $50 → $49
Current: $10.48
Upside: +367.56%
Axsome Therapeutics
Aug 5, 2025
Maintains: Buy
Price Target: $173 → $176
Current: $148.43
Upside: +18.57%
ProKidney
Jun 30, 2025
Downgrades: Underperform
Price Target: $3 → $1
Current: $2.17
Upside: -53.92%
Jun 11, 2025
Maintains: Buy
Price Target: $25 → $23
Current: $32.77
Upside: -29.81%
Jun 5, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $41.84
Upside: +9.94%
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $43.44
Upside: +215.38%
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $11.55
Upside: -13.38%
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $22.56
Upside: +33.01%
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $71.57
Upside: +39.72%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $7.64
Upside: +214.14%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $32.14
Upside: -3.55%
Mar 25, 2024
Maintains: Buy
Price Target: $600 → $550
Current: $3.87
Upside: +14,111.89%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $28.51
Upside: +1.72%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $43.68
Upside: +28.21%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $38.79
Upside: -22.66%
Aug 8, 2023
Downgrades: Underperform
Price Target: $100 → $50
Current: $8.69
Upside: +475.37%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $996.20
Upside: -49.81%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $1.49
Upside: +504.03%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $7.16
Upside: +249.41%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $2.11
Upside: +136.97%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $6.89
Upside: +291.87%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $1.32
Upside: +1,420.91%
Jul 15, 2020
Downgrades: Neutral
Price Target: $170 → $100
Current: $8.08
Upside: +1,138.39%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $225.60
Upside: -57.89%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $51.52
Upside: +16.46%
Oct 17, 2019
Reinstates: Neutral
Price Target: $37
Current: $25.71
Upside: +43.91%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $97.89
Upside: -8.06%